CompareRx Newsroom
GLP-1 news and today's most-asked questions
We monitor FDA actions, manufacturer announcements, pricing moves and search trends around the clock, then publish what actually changes the math for people buying GLP-1 care online.
Coverage areas: semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), retatrutide and next-generation obesity drugs, FDA approvals and regulatory action, clinical trial results, GLP-1 pricing, insurance coverage, telehealth developments, compounding regulation, and pharmaceutical company announcements. Written by the CompareRx editorial team under our editorial policy.
Eli Lilly’s orforglipron pill achieves 11% weight loss — paving way for needle-free alternatives
Eli Lilly’s oral weight-loss pill orforglipron achieves 11% weight loss in trials. Read what this needle-free, small-molecule GLP-1 means for US buyers.
Studies expose why some GLP-1 patients fail to lose weight — what DNA means for telehealth buyers
New genetics data from 23andMe and Stanford explains why some GLP-1 buyers fail to lose weight, highlighting genetic blocks and emotional eating patterns.
RxPros launches $89.97 flat-rate semaglutide — challenging telehealth price floors
RxPros launches flat-rate compounded semaglutide for $89.97 and tirzepatide for $119.97. See how this pricing reshapes the online GLP-1 market.
Novo partners with Novonesis on synbiotics — the plan to pair microbiome supplements with GLP-1s
Novo Nordisk and Novonesis target 2027 for clinical trial results testing synbiotic gut supplements alongside GLP-1 drugs to boost metabolic health.
FDA updates Orange Book semaglutide patents — what it changes for generic Ozempic timing
FDA updates the Orange Book registry as a key semaglutide patent approaches its March 2026 expiration. Learn what this means for generic Ozempic timing.
FDA targets bulk GLP-1 ingredients — what the proposed 503B ban changes for compounded buyers
The FDA proposes excluding semaglutide and tirzepatide from the 503B Bulks List, threatening the supply of low-cost compounded telehealth GLP-1s.
FDA warns against semaglutide salt forms — why base ingredients matter for compounded GLP-1 buyers
The FDA warns that semaglutide sodium and acetate are unauthorized salts with no legal compounding basis, raising safety risks for US GLP-1 buyers.
Survey reveals 15% of GLP-1 users are microdosing — how patients bypass standard doses online
An Evidation Health survey shows 15% of GLP-1 users are microdosing. Learn why patients are taking lower doses to cut side effects and costs.
Bariatric surgeries plunge 34% as GLP-1 use surges 140% — the cost shift for US buyers
New Wells Fargo and JAMA data show bariatric surgeries fell 34% as GLP-1 use surged 140%. What this metabolic shift means for US weight-loss buyers.
Employers turn to GLP-1 point solutions — how benefit managers are reshaping online weight loss access
As corporate GLP-1 coverage stabilizes, employers are deploying strict point-solution vendors to ration access, driving buyers to online telehealth.
Celon Pharma’s Reduzek matches Wegovy in trial — paving way for cheaper generic semaglutide
Celon Pharma’s Reduzek matches Wegovy and Ozempic in a new clinical trial, paving the way for affordable, FDA-approved generic semaglutide for US buyers.
Why am I not losing weight on Wegovy? — How to troubleshoot semaglutide non-response
Not losing weight on Wegovy or Ozempic? Learn why 10% to 17% of patients don't respond to semaglutide and how to troubleshoot your dose or swap drugs.
FDA approves second oral GLP-1 weight-loss pill — expanding needle-free choices for US buyers
The FDA has approved a second daily oral GLP-1 pill for chronic weight management, expanding needle-free clinical choices for US telehealth buyers.
FDA targets unapproved retatrutide compounding — closing next-gen peptide paths for online buyers
FDA targets unapproved compounders selling retatrutide and cagrilintide. Learn what warning letters mean for online buyers and GLP-1 safety.
Study reveals 48% of GLP-1 users turn to social media over doctors — the safety gap in online weight loss
A new peer-reviewed study shows 48% of GLP-1 users rely on social media over doctors for clinical advice. What this means for US weight-loss telehealth buyers.
UTMB launches tirzepatide anti-aging trial — opening longevity paths for GLP-1 buyers
Researchers at UTMB launch a clinical trial to test if Eli Lilly's tirzepatide (Zepbound) can slow biological aging by 10% to 15% in older US adults.
Novo launches OASIS-5 trial for lower oral Wegovy doses — what clinical microdosing means for US buyers
Novo Nordisk has launched the OASIS-5 trial to find the lowest effective dose for its oral Wegovy pill, a move that could cut side effects and costs.
Conagra designs food for the 'not-so-hungry' — what Big Food's GLP-1 pivot changes for US buyers
Big Food companies like Conagra are reformulating recipes and shrinking portion sizes to target GLP-1 users who experience drug-induced appetite loss.
Trial shows switching to oral GLP-1 maintains weight loss — providing a needle-free path for US buyers
A new clinical trial shows switching from injectable to oral GLP-1 therapy maintains weight loss, providing a needle-free maintenance option for US buyers.
Tirzepatide linked to higher hair loss than semaglutide — what alopecia data means for GLP-1 buyers
A new large-scale data analysis reveals tirzepatide (Zepbound) carries a higher risk of temporary hair loss than semaglutide (Wegovy). Read the pricing math.
Starbucks cuts employee GLP-1 coverage — driving retail workers to telehealth cash options
Starbucks ends employee GLP-1 weight-loss insurance coverage, forcing retail workers to choose between $1,300 retail costs and telehealth cash alternatives.
Researchers identify anti-inflammatory effects of GLP-1s — opening new off-label paths for pain and arthritis
Top metabolic researchers confirm GLP-1 drugs target chronic inflammation independently of weight loss, opening new off-label paths for arthritis and pain.
Major insurers restrict GLP-1 weight loss coverage — driving US buyers to telehealth cash options
Major commercial insurers will restrict or deny GLP-1 weight-loss coverage starting Jan 1, 2026, driving US buyers toward cash-pay telehealth options.
FDA limits bulk GLP-1 compounding — how the 503A vs 503B squeeze changes online weight-loss buying
The FDA limits bulk GLP-1 compounding by shutting down 503B outsourcing, pushing online buyers to smaller, patient-specific 503A pharmacies.
Nestlé launches $499 compounded tirzepatide — challenging telehealth startups with corporate scale
Nestlé enters the medical weight-loss market with a $499 compounded tirzepatide program, bringing corporate competition to telehealth GLP-1 startups.
FDA signals end of bulk GLP-1 compounding — what it changes for telehealth buyers
The FDA signals the end of bulk GLP-1 compounding. Learn how tightening 503A/503B rules impact low-cost compounded semaglutide and tirzepatide.
FDA approves oral Wegovy pill — opening a needle-free path for telehealth buyers
The FDA has approved Novo Nordisk’s daily oral Wegovy pill, giving US weight-loss telehealth buyers an official needle-free option. Here is the pricing math.
WADA monitors GLP-1 use in sports — shifting how US consumers view metabolic conditioning
As elite athletes like Serena Williams use tirzepatide, sports agencies debate whether GLP-1s are performance-enhancing. What this means for US buyers.
GLP-1 trials show success treating PCOS — opening new off-label paths for US women
Clinical trials show GLP-1 weight-loss drugs successfully treat PCOS, restoring ovulation and balancing hormones. What this means for US telehealth buyers.
Lawsuits target Novo Nordisk and Eli Lilly over eye strokes — what NAION risks mean for US GLP-1 buyers
A multi-district lawsuit consolidates over 130 cases alleging GLP-1 drugs like Wegovy cause permanent vision loss. What US buyers need to know.
FDA panel green-lights select peptides — signaling regulatory shift for custom compounders
An FDA panel green-lights select peptides for compounding and HHS moves 14 restricted peptides to Category 1, shifting the US custom compounding market.
Nestlé uses AI to target GLP-1 side effects — addressing muscle loss and 'Ozempic face'
Nestlé is leveraging AI and clinical data to develop targeted nutritional products that combat GLP-1 side effects like muscle loss and 'Ozempic face'.
FDA begins reviewing first generic tirzepatide applications — opening path to cheaper Zepbound alternatives
The FDA has started reviewing the first generic tirzepatide applications, marking the first major regulatory step toward cheaper Zepbound alternatives.
Dentist warns GLP-1s cause dry mouth — raising risk of rapid tooth decay for US buyers
Dentists warn that GLP-1 medications like Ozempic and Wegovy can cause severe dry mouth, lowering oral pH and accelerating tooth decay and gum disease.
FDA urges consumers to report unlawful online GLP-1 sales — how to spot and avoid counterfeit weight-loss drugs
The FDA is urging consumers to report illegal online drug sales amid a rise in counterfeit GLP-1s. Learn how to safely navigate telehealth options.
JAMA study reveals 10% of eating disorder patients misuse GLP-1s — forcing telehealth screening shift
A landmark JAMA Psychiatry study reveals that nearly one-third of individuals with eating disorders use GLP-1s, with over 10% misusing them to restrict food.
India launches $3.90 generic semaglutide — exposing the real cost of weight-loss drugs to US buyers
Indian generic drugmakers launch $3.90 semaglutide injections after Novo Nordisk's patent expires, signaling future price disruptions for US GLP-1 buyers.
Youth obesity surgery rates plummet to 4% — as GLP-1 therapies reshape pediatric care
A new JAMA Pediatrics study reveals youth obesity treatment is shifting rapidly from bariatric surgery to GLP-1 medications like Wegovy and Zepbound.
Medicare launches GLP-1 Bridge program — slashing weight-loss drug costs to $50 for seniors
The new Medicare GLP-1 Bridge program slashes the cost of weight-loss drugs to a flat $50 monthly copay for eligible US seniors. Learn if you qualify.
Australia reports 62 deaths linked to GLP-1 drugs — what safety data means for US buyers
Australia reports 62 deaths and 2,800 adverse events linked to GLP-1s. Doctors explain why association doesn't equal causation for US buyers.
Eli Lilly sues 14 generic rivals — delaying cheaper Zepbound and Mounjaro alternatives
Eli Lilly files 14 patent lawsuits against generic rivals in Delaware to block cheaper versions of Mounjaro and Zepbound. What this means for US buyers.
85% of eligible MS patients miss GLP-1 therapies — highlighting US healthcare access gaps
A new study shows 85% of eligible MS patients miss out on GLP-1s like Wegovy and Ozempic, exposing major care gaps for patients with complex conditions.
PBMs partner with TrumpRx to display insurance copays — exposing real GLP-1 costs
10 PBMs partner with the TrumpRx website to display commercial, Medicare, and Medicaid copays alongside direct-to-consumer cash prices for GLP-1 drugs.
Foundayo scripts climb as Wegovy pill hits 33% ceiling — reshaping the oral GLP-1 rivalry
Eli Lilly's Foundayo oral GLP-1 pill scripts surge to nearly 39,000, while Novo Nordisk's oral Wegovy hits a 33% franchise market share ceiling.
Harvard study reveals GLP-1s boost women's hiring rates by 27% — highlighting the career toll of weight bias
A new Harvard study reveals unemployed women taking GLP-1s are 27% more likely to get hired, highlighting the reality of workplace weight bias.
FDA warns 25 telehealth and compounding firms — revealing under-strength GLP-1 doses
The FDA issued warning letters to 25 telehealth and compounding firms over misleading GLP-1 marketing and distributed under-strength drug batches.
Medicare launches $50 copay cap for weight-loss GLP-1s — slashing senior costs
Medicare has expanded coverage to include certain GLP-1 weight-loss medications for a flat $50 monthly copay starting July 1, 2026. Learn if you qualify.
GLP-1 Users Cut Ice Cream Consumption by 10% — How Food Giants Are Pivoting to Wellness Treats
GLP-1 users have cut ice cream consumption by 10%, forcing brands like Ben & Jerry's, Blue Bunny, and Halo Top to pivot to high-protein, mini portions.
Employers cut GLP-1 coverage over soaring costs — driving US buyers to telehealth alternatives
With 31% of employers considering cutting GLP-1 benefits, patients face massive out-of-pocket costs, fueling a major shift toward telehealth.
Lawmakers press FDA over counterfeit GLP-1s — protecting telehealth buyers from dangerous imitations
Congress demands FDA action against counterfeit GLP-1 ingredients. Learn how to spot fake Ozempic and safely buy weight-loss drugs online.
1 in 5 US adults have tried a GLP-1 — what the telehealth boom means for safe buying
Scripps News highlights a massive GLP-1 milestone: 20% of US adults have tried these drugs. Learn what experts say about choosing a safe telehealth provider.
UK approves Eli Lilly's Foundayo pill — intensifying the global needle-free GLP-1 race
The UK has approved Eli Lilly's oral weight-loss pill Foundayo, intensifying the needle-free GLP-1 race against Novo Nordisk's oral Wegovy.
Novo Nordisk shifts to multi-drug obesity strategy — challenging Lilly with oral Wegovy and CagriSema
Novo Nordisk's CEO outlines a multi-drug obesity strategy to challenge Eli Lilly, highlighting oral Wegovy dominance and the upcoming CagriSema launch.
Glanbia raises profit forecast — surging GLP-1 protein demand triggers price hikes
Nutrition giant Glanbia raises profit forecasts as GLP-1 users drive massive demand for protein. Learn how rising whey costs impact your weight-loss budget.
CHAMPVA bans GLP-1s for weight loss — forcing military families to pay out of pocket
The VA has quietly restricted CHAMPVA GLP-1 coverage, banning weight-loss use. Learn what this means for military families and out-of-pocket costs.
FDA approves oral Wegovy pill — opening a needle-free path for telehealth buyers
FDA approves Novo Nordisk's oral Wegovy (semaglutide) daily pill. Read about what this means for injection-free weight loss and telehealth prices.
U.S. News Rates Found 4.6 Stars — Spotlighting Microdosing and Prior Authorization Support
U.S. News rates Found telehealth 4.6 out of 5 stars, highlighting its clinical support, insurance navigation, and compound microdosing options.
FDA Eases Generic GLP-1 Path — Streamlining Complex Peptides to Lower US Prices
The FDA is easing trial requirements for generic complex peptides. Learn how this regulatory shift will accelerate cheaper generic GLP-1s for US buyers.
Eli Lilly sues six companies over experimental retatrutide — protecting its next-gen obesity drug
Eli Lilly files six lawsuits against compounding pharmacies and peptide sellers over illegal black-market sales of its experimental obesity drug retatrutide.
Novo Nordisk Wins Injunction Against Compounded Semaglutide Spray
Novo Nordisk wins a Dutch court injunction against a compounded semaglutide nasal spray, signaling a major global legal crackdown on GLP-1 compounders.
U.S. News Unveils First GLP-1 Telehealth Platform Ratings
U.S. News & World Report has launched its first-ever ratings of GLP-1 telehealth platforms. Compare top-rated online providers like Amazon and Found.
Study: Tirzepatide Cuts Heart Attack, Stroke Risk by 33%
A new study shows Eli Lilly's tirzepatide (Mounjaro) lowers heart attack and stroke risk by 33% compared to sitagliptin in high-risk patients.
Eli Lilly Reports Surging Zepbound and Mounjaro Sales
Eli Lilly reports record Zepbound and Mounjaro sales, widening its lead over Novo Nordisk. Learn what this GLP-1 demand means for U.S. consumer prices.
Study: Medicare GLP-1 MFN Pricing Yields $56B in Savings
A JAMA Network Open study shows MFN pricing for Medicare GLP-1s would offset drug spending with $56.3B in savings. Learn what this means for GLP-1 costs.
Medicare Bridge Program Rules May Limit $50 GLP-1 Access
The $50 Medicare Bridge program for Wegovy and Zepbound faces severe primary care administrative hurdles. Learn what this means for GLP-1 access.
VA Launches Trial Testing Semaglutide for Alcohol Use Disorder
The U.S. Department of Veterans Affairs has launched the CRAVE clinical trial to test weekly semaglutide injections for treating alcohol use disorder.
Lilly and Novo Defeat Antitrust Lawsuit Over Compounded GLP-1s
A US federal judge has dismissed an antitrust lawsuit accusing Eli Lilly and Novo Nordisk of blocking compounded GLP-1 medications like Wegovy and Zepbound.
Amazon Pharmacy Offers Weight-Loss Drugs for $50 Under Medicare Bridge
Amazon Pharmacy is offering brand-name weight-loss drugs for $50/month to Medicare patients via the federal Bridge Program. Learn how to qualify.
CompareRx Daily
Today's GLP-1 news in your inbox
Five stories every morning on GLP-1 pricing, insurance coverage, shortages, and new provider deals — written by our newsroom and free to read.
Five stories a day. Free, no spam, unsubscribe in one click.
News is useful. Your match is actionable.
Answer a 90-second questionnaire and see the three providers that fit your budget, state and medication preference.
Get my top 3 matches